Docetaxel: Efficacy in First- and Second-Line Therapy of Advanced Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|23|6|1-3

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.6, 2004-11, pp. : 1-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 71-78

Karger

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy in Advanced Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 61-69

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy

By  

Oncology Research and Treatment, Vol. 28, Iss. 10, 2005-09 ,pp. : 499-502

Karger

Access to resources Recommend Favorite